What is the primary use of first-generation antipsychotics (FGAs)?

First-generation antipsychotics (FGAs) are primarily utilized for the acute and chronic management of schizophrenia and psychosis due to their dopamine antagonism, which significantly reduces the positive symptoms associated with these disorders such as hallucinations and delusions. These medications work by blocking dopamine D2 receptors in the brain, which has been foundational in addressing psychotic symptoms.

FGAs are not primarily used for the treatment of anxiety disorders, mood disorders, or insomnia; instead, they are specifically tailored to address the particular neurobiological imbalances present in psychotic disorders. This makes their role in the management of schizophrenia and psychosis central to psychiatric care. While some off-label uses may exist for FGAs, the established and most supported indication remains focused on psychotic symptoms, validating the use of FGAs in treating these conditions.